As a critical care pharmacist, you will care for more patients who need higher-than-average doses of continuous sedative infusions while mechanically ventilated. Continue to use your ICU liberation bundles, also known as ABCDEF or A2F bundles. These decrease sedative use by treating pain first and titrating to light sedation goals. But expect to need higher sedative doses to achieve light sedation in some patients, especially those with COVID-19. And patients with severe respiratory distress may need deeper sedation in order to breathe in sync with the mechanical ventilator. There aren’t hard-and-fast rules when treating these patients due to limited data. Consider these strategies...
Continue to generally use propofol first. Monitor for hypotension and symptoms of the rare but fatal propofol-related infusion syndrome (PRIS), unexplained metabolic acidosis, rhabdomyolysis, bradycardia, etc. There’s no consensus on a max propofol dose, but PRIS risk goes up with higher doses and longer durations. Think about allowing short-term use above your standard such as up to 80 mcg/kg/min for a few days. With higher doses, check triglycerides more frequently, such as a few times/week. Propofol is often stopped for triglycerides over 500 mg/dL. But consider a higher threshold, since pancreatitis is rare under 1,000 mg/dL. If giving high propofol doses for multiple days, think about adding other sedatives using lower doses of each medication may limit side effects. Also be prepared with alternatives when propofol is not an option due to issues such as shortages.
Consider dexmedetomidine for light sedation. Monitor for bradycardia and hypotension. Be aware, it doesn’t provide deep-enough sedation to use with a paralytic. If deep sedation is needed, add or switch to a midazolam drip (0.02 to 0.1 mg/kg/hour infusion). But limit use when able, since benzos (benzodiazepines) are linked to delirium risk. Think of a ketamine drip (0.05 to 0.4 mg/kg/hour) as an add-on option, especially with hypotensive patients, since it can raise blood pressure. It also has analgesic effects. Watch for increased heart rate and secretions and avoid in decompensated heart failure.
| Table (1). Medications for Procedural Sedation | ||
|---|---|---|
| Drug | IV Dosing (Adult) | Comments |
| Benzodiazepines | ||
| Midazolam | Initial dose:3,10 0.5 to 2.5 mg (or 0.05 mg/kg) given slowly over two minutes or more. Can repeat after about two minutes, and titrate slowly in small increments. Usual max total dose is 5 mg. Maintenance dose: 0.02 to 0.1 mg/kg/hour infusion. |
Often combined with an opioid for synergy.
Slightly slower onset, but longer duration compared to remimazolam. Reversal agent: flumazenil (0.2 mg IV over 15 seconds, may repeat in about one minute if needed). Max of 1 mg over five minutes. Monitor patients closely as resedation is possible if flumazenil wears off before midazolam. Lower doses may be needed in patients with kidney or liver impairment. |
| Opioids | ||
| Fentanyl | Initial dose: 25 mcg slowly over one to three minutes. Can repeat about every three to five minutes, as needed. Maintenance dose: 25 to 50 mcg or 0.35 to 0.5 mcg/kg every 30 to 60 minutes as needed. |
Often combined with a benzodiazepine for synergy.
Minimal histamine release compared to other opioids. Reversal agent: naloxone (0.4 mg IV initially, then 0.1 to 0.2 mg every two to three minutes as needed). Monitor patients closely as resedation is possible if naloxone wears off before fentanyl. |
| Other Procedural Sedation Options | ||
| Propofol (Diprivan, generics) |
Initial dose: 0.5 to 1 mg/kg followed by 0.5 mg/kg every one to three minutes as needed. Maintenance dose: 5 to 50 mcg/kg/minute. Titrate every 5 to 10 minutes in increments of 5 to 10 mcg/kg/minute. Some patients require up to 70 mcg/kg/minute, which can increase risk of propofol infusion syndrome. |
Carries a risk of hypotension and respiratory depression.
Similar onset and recovery time to remimazolam. Lower doses may be needed in elderly patients, due to decreased volume of distribution and clearance. No reversal agent available. Contraindicated in patients who have soybean or egg allergies or sensitivities. Patients may experience pain on injection. |
| Ketamine | Initial: 1 to 3 mg/kg. Can repeat 0.5 to 1 mg/kg doses every 5 to 10 minutes as needed. Maintenance dose: 0.05 to 0.4 mg/kg/hour. |
Combines anesthesia and analgesia in one medication. Use associated with risk of hypertension or increased heart rate. Can cause recovery agitation (emergence phenomena), transient laryngospasm, and emesis.
No reversal agent available. |
| Etomidate | Initial: 0.1 to 0.2 mg/kg over 30 to 60 seconds followed by 0.05 mg/kg every 3 to 5 minutes as needed. |
Hypnotic only; has no analgesic properties. Minimal cardiac effects. Patients may experience:
|
| Dexmedetomidine (Precedex) |
Initial: 1 mcg/kg over 10 minutes followed by a maintenance infusion (0.2 to 1 mcg/kg/hr). |
Does NOT cause respiratory depression, but commonly leads to dose-related hypotension and bradycardia. Not as routinely used as other options (e.g., propofol, midazolam with fentanyl) and some even question its use as sole sedative. No reversal agent available. Lower doses may be needed in patients with liver impairment. |
REFERENCES
-
Adams CD, Altshuler J, Barlow BL, Dixit D, Droege CA, Effendi MK, Heavner MS, Johnston JP, Kiskaddon AL, Lemieux DG, Lemieux SM, Littlefield AJ, Owusu KA, Rouse GE, Thompson Bastin ML, Berger K. Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19. Pharmacotherapy. 2020 Dec;40(12):1180-1191. Available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2471
Chanques G, Constantin JM, Devlin JW, Ely EW, Fraser GL, Gélinas C, Girard TD, Guérin C, Jabaudon M, Jaber S, Mehta S, Langer T, Murray MJ, Pandharipande P, Patel B, Payen JF, Puntillo K, Rochwerg B, Shehabi Y, Strøm T, Olsen HT, Kress JP. Analgesia and sedation in patients with ARDS. Intensive Care Med. 2020 Dec;46(12):2342-2356. Available at: https://link.springer.com/article/10.1007/s00134-020-06307-9
Devlin JW, O'Neal HR Jr, Thomas C, Barnes Daly MA, Stollings JL, Janz DR, Ely EW, Lin JC. Strategies to Optimize ICU Liberation (A to F) Bundle Performance in Critically Ill Adults With Coronavirus Disease 2019. Crit Care Explor. 2020 Jun 12;2(6):e0139. Available at: https://journals.lww.com/ccejournal/Fulltext/2020/06000/Strategies_to_Optimize_ICU_Liberation__A_to_F_.16.aspx
Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019 Apr;122(4):448-459. Available at: https://www.bjanaesthesia.org/article/S0007-0912(19)30010-8/fulltext
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. Available at: https://journals.lww.com/ccmjournal/Fulltext/2018/09000/Clinical_Practice_Guidelines_for_the_Prevention.29.aspx